Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

IMPORTANCE: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Hengwei, Shi, Jimin, Luo, Yi, Tan, Yamin, Zhang, Mingming, Lai, Xiaoyu, Yu, Jian, Liu, Lizhen, Fu, Huarui, Huang, He, Zhao, Yanmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841467/
https://www.ncbi.nlm.nih.gov/pubmed/33502484
http://dx.doi.org/10.1001/jamanetworkopen.2020.34750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841467/
https://www.ncbi.nlm.nih.gov/pubmed/33502484
http://dx.doi.org/10.1001/jamanetworkopen.2020.34750

Ejemplares similares